Eris Lifesciences Ltd has achieved a remarkable milestone by setting a record for screening and educating the maximum number of neuropathy patients through patient awareness camps across India. A total of 1,427 patients were screened for peripheral neuropathy between May 1 and June 15, 2025, marking a major step forward in proactive healthcare and public education.
The record was officially recognized on June 27, 2025, highlighting Eris Lifesciences’ dedication to enhancing awareness of nerve-related disorders. The screenings were carried out using the NEURO TOUCH device — a cutting-edge diagnostic tool that provides comprehensive assessments of nerve function. This technology played a crucial role in enabling healthcare professionals to effectively diagnose, monitor, and manage neuropathic conditions during the camps.
The initiative not only emphasized early detection but also educated patients on symptoms, risks, and lifestyle management strategies related to neuropathy, a commonly overlooked condition especially among diabetic populations.
This achievement reflects Eris Lifesciences Ltd’s commitment to public health advocacy, innovation in diagnostics, and accessibility of care. With peripheral neuropathy on the rise due to lifestyle diseases, this awareness campaign has been a timely and commendable effort in empowering communities across India.
